Jumpstarting the Transformation to True Personalized Medicine: Potential Catalysts and Keystones

Table of Contents

• Table of Contents
• Health Industry Insights Opinion
• In This Report
  • Brief Description of the Solution
• Situation Overview
  • Current Environment
  • Table: Cardiovascular Adverse Events for Selected Drugs
  • Management Challenges
  • Emerging Process Keystones and Other Supporting Knowledge Infrastructure
    • The $1,000 Genome
    • Whole Genome Sequences from Individuals
    • Advances in Systems Biology
    • Advances in Translational Medicine
  • Potential Catalysts to Accelerate Personalized Medicine Adoption
    • Large-Scale Genotyping of Clinical Trial Participants
    • Routine Post-Clinical Trial Genotyping for All Adverse Event Patients
    • Development of Minable EHRs Containing Whole Genome Data for Adverse Event Patients
    • Biobanking of Adverse Event Tissues
  • Strategic Efforts to Watch
  • Success Factors
  • Factors Affecting Adoption
• Future Outlook
  • Remaining Challenges
  • Market Trends
  • Potential Pitfalls
• Essential Guidance
  • Actions to Consider
    • Pharma
    • Healthcare Providers
    • Healthcare Payers
    • Patient Advocacy Groups
• Learn More
  • Related Research
  • Synopsis